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Polymorphism in CYPlA and CYP2D6Genes:
Possible Association with Susceptibility to
Lung Cancer
by Ari Hirvonen,1 Kirsti Husgafvel-Pursiainen,1 Sisko
Anttila,1 Antti Karjalainen,1 and Harri Vainiol2
Polymorphism ofCYP2D6gene encodingfordebrisoquine hydroxylase wasdeterminedgenotypicallyfor94
controls and 77 lung cancer patients using a polymerase chain reaction-based application. Both ofthe point
mutations that give rise to deficient alleles ofthe CYP2D6 gene are detectable by this method. Out ofthe 94
healthy controls, 3 individuals (3.2%) had poor metabolizer (PM) genotypes, whereas no PM genotypes were
detected in the lung cancer patient group. We observed no difference in the allelic frequencies for either
homozygous extensive metabolizers (EMs) or heterozygous EMs between the lung cancer patients and the
healthy controls. However, the absence ofthe poor metabolizer genotype (0/77) in the lung cancer patients is
compatible with the hypothesis thatthere is an increased riskoflungcancerforindividuals who are extensive
metabolizers ofdebrisoquine. Another member ofthe cytochrome P450 gene superfamily that has attracted
interestforitspotentialrole inhumanpulmonarycarcinogenesis istheCYPIAI gene. InCYPIAJ genestudies,
a polymorphic site assessable to MspI gives rise to two different hybridizable fragments in a Southern blot
analysis (alleles Cl andC2,respectively). The C2C2 genotype has previouslybeen associated with an increased
risk oflung cancer. So far 74 lung cancer patients, 30 patients with lung diseases other than cancer, and 118
healthy controls have been studied for CYPIAI gene polymorphism. No association between the MspI
restriction fragment lengthpolymorphism intheCYPIAJ gene andlungcancersusceptibility hasbeenfound.
Introduction
Individual differences in the ability to metabolize
xenobiotics may be a key factor in the genetic predisposi-
tion, or host susceptibility, to various carcinogens (1,2).
The cytochrome P450-dependent mono-oxygenases are
important in the metabolism of environmental carcino-
gens. Among the most studied genetic variables concern-
ing P450 enzymes are the polymorphisms of the genes
CYP2D6 and CYPlAl, which encode for debrisoquine
4-hydroxylase and aryl hydrocarbon hydroxylase, respec-
tively (3). Both polymorphisms have recently been associ-
ated with susceptibility to lung cancer (1,2).
The debrisoquine metabolism phenotype has been
determined conventionallybyadministering the test drug
and subsequently determining theurinarymetabolic ratio
(4). However, thisphenotypingprocedure has some limita-
tions because of confounding and the potential adverse
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effects ofthedrugs (5). Extensivemetabolizers (EMs) can
either be homozygous or heterozygous for the normal
allele, the metabolic ratio being lower in the latter, but the
two genotypes cannot be reliably distinguished by phe-
notyping (6).
Recently, a functional CYP2D6 allele and two related
genes, designated CYP2D7 and CYP2D8P (pseudogene),
have been isolated and completely sequenced (7). This has
allowed CYP2D6 genotyping using polymerase chain
reaction (PCR)-based methods (8,9). These methods do
not have the same limitations as the conventional phe-
notyping analyses and they can be accomplished using
only tiny amounts ofwhite blood cell DNA.
AnotherP450enzymethatisofconsiderableinterestfor
its potential role in human pulmonary carcinogenesis is
aryl hydrocarbon hydroxylase (AHH). AHH activity can
be induced by polycyclic aromatic hydrocarbon (PAH)
components ofcigarettesmokecondensate(1041).Asignif-
icant correlation between high AHH-inducibility and
enhanced risk of bronchogenic carcinoma in cigarette
smokers was originally reported by Kellerman et al. (12),
and subsequent studies have led to the conclusion thatthe
cigarettesmokerswiththehighinducibilityphenotype are
several times more prone to bronchogenic carcinoma than
smokers with the low inducibility phenotype (13). TheHIRVONEN ET AL.
CYPlAl gene encoding for AHH thus attracts particular
interest for its role in individual inducibility status.
Restriction fragment length polymorphisms (RFLPs)
are now commonly used for diagnosing and predicting a
growingnumberofclinicaldisordersandforhumanfamily
studies. Determination of the cDNA sequence of the
CYPiA1 gene (14) has made it possible to look for the
RFLPs in the CYPlA1 gene too. In the earlyattempts, no
associationbetween RFLPpatterns andAHHinducibility
was noted (14). The recent discovery of MspI polymor-
phism in the last intron ofthe CYPlAl gene (15), however,
has led to the detection of cosegregation of the P450IA1
phenotype and MspI RFLP patterns (16). In addition, a
strong correlationbetween enhancedlungcancerriskand
MspI RFLPpatterns oftheCYPlAl genewas discovered
in a Japanese study (17).
Inthis study, acombined application (18) oftworecently
described PCR-based methods (8,9) for determinating
debrisoquine hydroxylase polymorphism in leukocyte
DNAwas used to studythe distribution ofextensive (EM)
and poor metabolizer (PM) genotypes in Finnish lung
cancer patients and in control subjects. The method used
was estimated to detect at least 95% ofthe known allelic
variants of the PM genotype (18). The study populations
were also screened for the MspI RFLP in the CYPlAl
gene.
Subjects and Methods
Subjects
Three groups were examined in this study: the first
group comprised 91 healthy blood donors at the Finnish
Red Cross Blood Transfusion Service (all males) and 27
volunteers (12males, 15females) employed atthe Institute
ofOccupational Health in Helsinki, The other two groups
comprised 77 lung cancer patients (64 males, 13 females)
and 30 patients with lung diseases other than cancer (21
males, 9 females), respectively.
The patients came to Helsinki University Central Hos-
pital over a 3-year period for surgical pulmectomy or
lobectomybecause they had suspected, operable lung car-
cinoma. The mean age for the lung cancerpatients was 62
years (SD 9.7), and most of them were either current
cigarette smokers or ex-smokers for more than 3 years
before surgery. According to interview data, only seven
patients had never smoked. The blood samples were
obtained the daybefore surgery. None ofthe patients had
received chemotherapy orradiotherapy. The study design
was approved by the local ethics committees.
DNA Analyses
DNAs were isolated from bood samples (10-20 mL)
obtained from all the subjects. The DNA samples were
analyzed by a PCR-genotyping assay and by a MspI
RFLP analysis.
The PCR-based CYP2D6 genotyping analyses were
performed as described elsewhere (18). Briefly, genomic
DNA was first amplified by PCR using two different
oligonucleotide pairs. One ofthePCRfragmentswas then
digested with the restriction enzyme BstNI. Absence of
therestriction siteindicated aspecificpointmutation. The
other fragment was used as a template for two allele
specific PCR reactions: one with a wild-type specific
primerpair and the otherwith a mutation specific primer
pair, which detected the second point mutation studied.
The final samples were separated electrophoretically on a
1.8% agarose gel and visualized by UV-irradiation using
ethidium bromide staining.
The CYPlAl genotyping analysis on lymphocyte DNA
was performed in principle as described by Kawajiri and
co-workers (17) and given in detail elsewhere (19).
Statistical Analyses
The chi-square (contingency tables) test with Yates'
correlation was used to test the associations between the
different genotypes and cancerincidence, as well as other
clinical parameters.
Results and Discussion
The electrophoresis results of the combined PCR-
genotypingoftheCYP2D6geneandtheRFLPanalysisof
the CYPlA1 gene are shown in Figure 1.
Thedistribution ofdifferentCYP2D6 genotypes among
the lung cancer patients and voluntary blood donor con-
trols is shown in Table 1. All the lung cancer patients
studied were assessed as either homozygous for two nor-
malalleles orheterozygous foronenormaland onemutant
allele (i.e., they all had the EM genotype). Except for the
lack of lung cancer patients with a PM genotypes, the
allelic frequencies in the two populations were quite simi-
lar.Thepercentage ofobservedPMsinthecontrolpopula-
tion was 3.2%, which fell well within the range obtained
previously in Finnish phenotypic studies (20). A PCR-
based CYP2D6 genotyping approach similar to ours was
applied in a recent study by Daly and co-workers and
yielded agoodcorrelationbetweenthedebrisoquinemeta-
bolic ratio and genotype (21).
The RFLP polymorphism in the CYPIAl gene was
detected by the presence or absence of the MspI site
locatedinthe3' endofthegene (17)resultinginC2andCl
alleles, respectively. The distribution of the different
CYPlAl genotypes in the three populations is shown in
Table 1. The resultsindicate no difference in the genotypic
frequencies between lung cancer and control populations.
Furthermore, neither of the studied genotypes revealed
anydifferences between the various histological subtypes
oflung cancer (18,19).
These conclusions on the CYPlAl genotypes are in
contrastto theresults ofKawajiri etal. (17)who showed a
statistically significant association between the rare C2
allele and certain types of lung cancer. In the Japanese
study, frequencies of genotypes among lung cancer
patients were significantly different from those among
healthy controls. In relation to histological types of lung
cancer, the squamous cell carcinoma gave the most
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Table 1. Distribution ofCYP2D6 and I
CYP2D6
Lung cancer patients (n=77)
Squamous cell carcinoma (n=39)
Adenocarcinoma (n=30)
Small cell carcinoma (n=5)
Large cell carcinoma (n=3)
Healthy controls (n=94)
CYPlAl
Lung cancer patients (n=74)
Squamous cell carcinoma (n=38)
Adenocarcinoma (n=28)
Small cell carcinoma (n=5)
Large cell carcinoma (n=3)
Patients with other lung diseases
(n=30)
Healthy controls (n=118)
(
Abbreviations: EM, extensive-metabolizer
zygous extensive-metabolizer genotypes; PA
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FIGURE 1.Examples oftheelectrophoresis results from the CYP2D6 and CYPLAl genotypinganalyses. (A) The six differentgenotypes from CYP2D6
PCR-based analysis. Genotypes are resolved by combining the information from the three parallel lanes; EM, homozygous extensive metabolizer
genotype; HEM, heterozygous EM genotypes; PM, PM genotypes. (B) Autoradiogram ofCYPlAl MspI restriction fragment length polymorphism
analysis showing the genotypes C2C2 (lane 2), C1C2 (lanes 5-7, 11,12) and CiCl (lanes 1,3,4,8-10,13,14).
CYPIAJ genotypes. remarkabledeviationfromthegenotypefrequenciesinthe
EM HEM PM healthy controls; about 5-fold risk of C2C2 type was
62 15 0 calculated for this smoking related type of lung tumor.
30 9 0 Recently, the Japanese group also reported that the 24 6 0 smokers with the susceptible genotype were at a remark-
53 0 0 ablyhigh risk at alow dose level ofcigarette smoking and
73 18 3 thatthedifferencebetweengenotypeswasreducedathigh
rlCl C1C2 C2C2 dose levels (22). In contrast to to the Japanese findings, in a similar
3612 7 0 study concerning Norwegian lung cancer patients, no
23 5 0 statisticallysignificant differencesin allelicfrequencies or
5 0 0 distribution of the CYPlAl genotypes were seen (23).
3 0 0 Furthermore, the proportion of the rare genotype C2C2
25 4 1 was very smallcompared to theJapanese population.
91 25 2 In the present preliminary study, which included rela-
genotype; HEM, hetero- tively small studypopulations, the association ofCYPlA4
'A,poor-metabolizer geno- and CYP2D6 genes with individual susceptibility to lung
cancer could neither be confirmed nor contradicted. It is
pm hem em
IR --588 bp
'-363 bp
'-254 bp
s-4109 bp
A
1 2 3 4 5 6 7 8 9 10 11 12 13 14
* s
..-......... ..... t >.
-. 4 ;.s t. -,. -. ..*<';P,'
.,.,.,.,. ..
.. ..:.....:,',:.':::'.,.j-,:..'.,:.::..>.
'''t :" 9,,' 9' ; .' -.
2.5 kb
1.9 kb
B
m
I
ill112 HIRVONEN ET AL.
evident that more studies involving larger study popula-
tions from various ethnic subgroups are needed to draw
any conclusions concerning the possible association
between polymorphisms in the cytochrome P450 gene
superfamily and lung cancer risk.
We thank Thula Suitiala for her skilled technical assistance and Anne
Hand for the linguistic revision.
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